Products for Research Use Only
RegisterLogin

Lidorestat

CAT: 0804-HY-106198-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-106198-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation[1][2][3].
CAS Number
245116-90-9
Product Name Alternative
IDD-676
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Aldose Reductase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/lidorestat.html
Purity
99.50
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OC(CN1C(C=CC=C2)=C2C(CC3=NC(C(F)=C(F)C=C4F)=C4S3)=C1)=O
Molecular Formula
C18H11F3N2O2S
Molecular Weight
376.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Noh HL, et al. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J Pharmacol Exp Ther. 2009 Feb;328 (2) :496-503.|[2]Van Zandt MC, et al. Discovery of 3-[ (4,5,7-trifluorobenzothiazol-2-yl) methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. J Med Chem. 2005 May 5;48 (9) :3141-52.|[3]Maccari R, et al. Identification of new non-carboxylic acid containing inhibitors of aldose reductase. Bioorg Med Chem. 2010 Jun 1;18 (11) :4049-55.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
BA7160-50Lidorestat
MBS5811484Lidorestat monohydrate

Popular Products